Dr. Michael Flavin is the president and founder of MediChem Research, Inc. He received a Bachelor of Science in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry with an emphasis on Synthetic Organic Chemistry from the University of Illinois at Chicago, and completed a Postdoctoral Fellowship in Synthetic Organic Chemistry at Harvard University. Prior to Dr. Flavin’s launching of MediChem Research, Inc. in 1987, he worked as a Senior Research Associate for Baxter International for 2 years. Dr. Flavin oversees the research and development of (+)-calanolide A, a naturally occurring compound identified from the rainforests in Sarawak, Malaysia, which is the primary focus of Sarawak MediChem Pharmaceuticals, Inc. Dr. Flavin is also an Adjunct Professor for both the Graduate School of Business at Benedictine University and the Department of Medicinal Chemistry and Pharmacognosy at the University of Illinois at Chicago.

Formerly senior vice president and chief financial officer at BioGenex Laboratories, Inc., San Ramon, CA, where his accomplishments included raising the company’s first two rounds of venture capital funding and positioning the company for an IPO. Previously, he was president and chief operating officer of Option Care, Inc., in Bannockburn, IL, a publicly traded NASDAQ company with $250 million in annual revenues.

Mr. Flavin has been with Medichem Research Inc., Since 1991. He holds a BS in Business Administration from Marquette University and an MBA. in Finance from the Lewis University Graduate School of Management. As Medichem's Director of Financial Operations from 1991 and until 1996, Mr. Flavin successfully designed and implemented computerized financial reporting systems for control and performance measurement. Mr. Flavin was also responsible for developing and executing unique corporate financing strategies, including a partnership with the Spanish pharmaceutical firm Laboratories Vita and the Sarawak Medichem Pharmaceuticals joint venture.

Since 1996, as Executive Vice President and Chief Operating Officer at Medichem, Mr. Flavin has grown revenues and performance with his team's scientific and project management skills. He has built the Business Development and Customer Service Groups into unique competitive strengths in Medichem's marketplace. The organizational structure and systems platform that Mr. Flavin has established is designed to handle the increase in project volume and research the complexity expected from Medichem's

Dr. McDonnell's patent practice at McDonnell Boehnen Hulbert & Berghoff has primarily involved biotechnology, pharmaceuticals, diagnostics and related healthcare matters. He has been particularly active in advising emerging high technology companies and groups investing in such a companies. In addition to rendering comprehensive opinions on all aspects of Biotechnology related technology, Dr. McDonnell is noted for his creative strategies and alternative approaches to the accomplishment of intellectual property business objectives. He has extensive experience in complex lawsuits involving major biotechnology products. Dr. McDonnell has over twenty years of experience in pharmaceutical and diagnostic patent matters. Before founding the firm he was Chief Patent and Trademark Counsel at G.D. Searle, where he secured a five-year extension of the Aspartame patent and directed the brand ingredient strategy for Nutrasweet. Dr. McDonnell was also head of diagnostic patent operations at Abbott Laboratories for five years. Mr. McDonnell earned his Ph.D. in Organic Chemistry from Iowa State University (1968). Prior to entering the practice of law, Dr. McDonnell was Assistant Professor of Chemistry at Illinois Institute of Technology in Chicago. He is a member of the American Intellectual Property Law Association and the Association of Corporate Patent Counsels.